For forty years, no new antibiotic class targeting Enterobacteriaceae infections has come on the market. If all goes to plan, this overlong dry spell is coming to an end soon: With the help of Evotec, Nosopharm plans to advance its lead candidate into clinical development. The two companies announced a new partnership with the goal to launch a Phase I trial for compound NOSO-502 for the treatment of complicated Urinary Tract Infections and complicated Intra-Abdominal Infections.
NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins (ODLs). It inhibits the bacterial ribosome with a new mechanism of action and is intended for the treatment of nosocomial infections caused by Enterobacteriaceae, including polymyxin– and carbapenem-resistant Enterobacteriaceae. Enterobacteriaceae – which include, among others, Escherichia coli and Klebsiella pneumoniae – were listed as a priority pathogen by the WHO in 2017 for the R&D of new antibiotics. NOSO-502 has proven to be effective in vivo in Enterobacteriaceae infection models. Nosopharm expects to launch first-in-human studies with the compound in 2021.
In addition, the partners will focus on the development of a second-generation Odilohabdin drug candidate for the treatment of hospital-acquired pneumonia and ventilation-associated pneumonia.
"It’s exciting to see the development of an entirely new antibiotic class, which is crucial in these times of rising antibiotic resistance,” said Evotec CSO Cord Dohrmann.